A major scientific journal has been forced to retract its 2000 study on the safety of Roundup herbicide, a widely used chemical linked to cancer. The paper, published in Regulatory Toxicology and Pharmacology, was cited by regulators worldwide as evidence that glyphosate-based weed killers posed no health risks to humans.
However, an investigation into the paper's origins has revealed serious ethical concerns over its authorship, methodology, and potential conflicts of interest. The study's conclusions were based solely on unpublished data from Monsanto, the manufacturer of Roundup, ignoring other outside research.
The retraction is a result of an email exchange between Monsanto officials and their internal researchers, which was uncovered in litigation brought by cancer patients suing the company. The emails showed that the paper's authors had been ghostwritten by Monsanto scientists, and that the company had played a significant role in shaping the study's findings.
In one email, Lisa Drake, then a Monsanto government affairs official, wrote that the paper was "the" reference on Roundup safety, and that it would be used to defend the product against lawsuits. The company executive Hugh Grant praised the research team, saying they had done "very good work."
The retraction is a significant blow to the credibility of scientific journals and regulators who have relied on the study's findings. Brent Wisner, one of the lead lawyers in the Roundup litigation, said that the paper was an example of how companies can undermine the peer-review process through ghostwriting and biased interpretations.
The EPA has stated that it is not relying on the retracted article to develop its regulatory conclusions on glyphosate, but rather on a comprehensive review of over 6,000 studies. However, the agency's updated human health risk assessment for glyphosate is currently due for release in 2026, which will rely on some of the same unpublished data from Monsanto.
The retraction has sparked outrage among cancer patients and their advocates, who have long argued that the company's influence over scientific research has contributed to the delayed recognition of Roundup's potential health risks. The case highlights the need for greater transparency and accountability in scientific research and regulation.
However, an investigation into the paper's origins has revealed serious ethical concerns over its authorship, methodology, and potential conflicts of interest. The study's conclusions were based solely on unpublished data from Monsanto, the manufacturer of Roundup, ignoring other outside research.
The retraction is a result of an email exchange between Monsanto officials and their internal researchers, which was uncovered in litigation brought by cancer patients suing the company. The emails showed that the paper's authors had been ghostwritten by Monsanto scientists, and that the company had played a significant role in shaping the study's findings.
In one email, Lisa Drake, then a Monsanto government affairs official, wrote that the paper was "the" reference on Roundup safety, and that it would be used to defend the product against lawsuits. The company executive Hugh Grant praised the research team, saying they had done "very good work."
The retraction is a significant blow to the credibility of scientific journals and regulators who have relied on the study's findings. Brent Wisner, one of the lead lawyers in the Roundup litigation, said that the paper was an example of how companies can undermine the peer-review process through ghostwriting and biased interpretations.
The EPA has stated that it is not relying on the retracted article to develop its regulatory conclusions on glyphosate, but rather on a comprehensive review of over 6,000 studies. However, the agency's updated human health risk assessment for glyphosate is currently due for release in 2026, which will rely on some of the same unpublished data from Monsanto.
The retraction has sparked outrage among cancer patients and their advocates, who have long argued that the company's influence over scientific research has contributed to the delayed recognition of Roundup's potential health risks. The case highlights the need for greater transparency and accountability in scientific research and regulation.